Clinical Trials Directory

A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is now accepting new patients for this trial.

Investigator(s):

Intervention(s):

  • drug : Fulvestrant
  • drug : Trastuzumab
  • drug : Neratinib

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Karen Lau
650-723-0658
Recruiting

Footer Links: